These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21514794)

  • 41. Cost-Sharing Increase, Medication Adherence, and Hospitalizations in Schizophrenia Patients: A Natural Experiment.
    Serra-Burriel M; Hurtado I; Sanfélix-Gimeno G; García-Sempere A; Peiró S
    Clin Pharmacol Ther; 2021 Dec; 110(6):1490-1497. PubMed ID: 33973231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-adherence to antipsychotic medication regimens: associations with resource use and costs.
    Knapp M; King D; Pugner K; Lapuerta P
    Br J Psychiatry; 2004 Jun; 184():509-16. PubMed ID: 15172945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Teaching medication management skills to schizophrenic patients.
    Eckman TA; Liberman RP; Phipps CC; Blair KE
    J Clin Psychopharmacol; 1990 Feb; 10(1):33-8. PubMed ID: 1968471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New study designs for new antipsychotics.
    Kahn RS
    Psychopharmacology (Berl); 2002 Jun; 162(1):92. PubMed ID: 12141275
    [No Abstract]   [Full Text] [Related]  

  • 45. The SEMITEP Trial: Less May Be More.
    Albers P
    Eur Urol; 2022 Aug; 82(2):180-181. PubMed ID: 35606232
    [No Abstract]   [Full Text] [Related]  

  • 46. A randomized trial of aspirin and beta-carotene among U.S. physicians.
    Hennekens CH; Eberlein K
    Prev Med; 1985 Mar; 14(2):165-8. PubMed ID: 3900975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration.
    Rosenheck R; Anand ST; Kurtz SG; Hau C; Smedberg D; Pontzer JF; Ferguson RE; Davis CR
    Trials; 2023 Feb; 24(1):85. PubMed ID: 36747254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.
    Novick D; Montgomery W; Treuer T; Koyanagi A; Aguado J; Kraemer S; Haro JM
    Patient Prefer Adherence; 2017; 11():1019-1025. PubMed ID: 28652711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.
    Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
    Neuropsychiatr Dis Treat; 2014; 10():1125-31. PubMed ID: 25018631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress in compliance research and intervention: a commentary.
    Rosenheck R
    World Psychiatry; 2013 Oct; 12(3):227-9. PubMed ID: 24096781
    [No Abstract]   [Full Text] [Related]  

  • 51. Veteran subjects willingness to participate in schizophrenia clinical trials.
    Hoblyn JC; Rosenheck RA; Leatherman S; Weil L; Lew R;
    Psychiatr Q; 2013 Jun; 84(2):209-18. PubMed ID: 23143523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.
    Basu A
    Schizophr Res; 2004 Dec; 71(2-3):445-62. PubMed ID: 15474916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How do clinical trial participants compare to other patients with schizophrenia?
    Barnett PG; Scott JY; Rosenheck RA;
    Schizophr Res; 2011 Aug; 130(1-3):34-9. PubMed ID: 21514794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.